MEK Inhibitor Binimetinib Shows Limited Activity in Low-Grade Serous Ovarian Carcinomas

0 reviews

Danielle Ternyila

Targeted Oncology

Binimetinib demonstrated activity as treatment of patients with low-grade serous ovarian carcinomas in the randomized phase 3 MILO/ENGOT-ov11 study.

I'm interested in this

Share with others

Write the first review

Join now

to leave a review or read peer reviews!

Resource tags

FOAMed

Oncology

Physician

Show all tags

Access

Free

Visit Site

Share with others

I'm interested